High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease

Journal of Neuroscience Research

Volumn 86, Issue 9, 2008, Pages 2083-2090

  Jia, Haiqun ^a,b   Li, Xin ^a   Gao, Hongxiang ^a   Feng, Zhihui ^a,b   Li, Xuesen ^a,b   Zhao, Lei ^a   Jia, Xu ^a   Zhang, Hongyu ^a   Liu, Jiankang ^c  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ketoglutarate dehydrogenase; Climbing ability; Complex I; DNA damage; Protein oxidation

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 8 HYDROXYDEOXYGUANOSINE; ALPHA SYNUCLEIN; CARBONYL DERIVATIVE; NICOTINAMIDE; OXIDIZING AGENT; OXOGLUTARATE DEHYDROGENASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; CELL CULTURE; CELL VIABILITY; CLIMBING; COMET ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE MODEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DROSOPHILA MELANOGASTER; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NERVE DEGENERATION; NEUROBLASTOMA CELL; NEUROPROTECTION; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; TRANSGENIC ANIMAL;

ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DNA DAMAGE; DNA, MITOCHONDRIAL; DROSOPHILA; HUMANS; KETOGLUTARATE DEHYDROGENASE COMPLEX; MITOCHONDRIA; MOTOR ACTIVITY; NEUROBLASTOMA; NIACINAMIDE; OXIDATIVE PHOSPHORYLATION; PARKINSONIAN DISORDERS;

EID: 48249148799     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21650     Document Type: Article

References (31)

1. Adams JD, Odunze I. 1991. Oxygen free radicals and Parkinson's disease. Free Rad Biol Med 10:161-169.
2. Ames BN, Elson-Schwab I, Silver EA. 2002. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K(m)): relevance to genetic disease and polymorphisms. Am J Clin Nutr 75:616-658.
3. Ames BN, Suh JH, Liu J. 2006. Enzymes lose binding affinity for coenzymes and substrates with age: A strategy for remediation. In: Kaput J, editor. Nutrigenomics: Concerpts and Technologies. Hoboken, NJ: John Wiley and Sons, Inc. p 277-291.
4. Anderson DW, Bradbury KA, Schneider JS. 2006. Neuroprotection in Parkinson models varies with toxin administration protocol. Eur J Neurosci 24:3174-3182.
5. Anderson JW, Johnstone BM, Remley DT. 1999. Breast-feeding and cognitive development: a meta-analysis. Am J Clin Nutr 70:525-535.
6. Beal MF. 2003. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann Neurol 53:S39-S47, discussion S47-S38.
7. Beal MF. 2004. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr 36:381-386.
8. Birkmayer JG, Vrecko C, Volc D, Birkmayer W. 1993. Nicotinamide adenine dinucleotide (NADH) - a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Acta Neurol Scand 146:32-35.
9. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA. 2002. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 277:45099-45107.
10. Cosi C, Marien M. 1998. Decreases in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide. Brain Res 809:58-67.
11. Ebadi M, Govitrapong P, Sharma S, Muralikrishnan D, Shavali S, Pellett L, Schafer R, Albano C, Eken J. 2001. Ubiquinone (coenzyme Q10) and mitochondria in oxidative stress of parkinson's disease. Biol Signals Recept 10:224-253.
12. Feany MB, Bender WW. 2000. A Drosophila model of Parkinson's disease. Nature 404:394-398.
13. Feany MB, Pallanck LJ. 2003. Parkin: a multipurpose neuroprotective agent? Neuron 38:13-16.
14. Haramaki N, Han D, Handelman GJ, Tritschler HJ, Packer L. 1997. Cytosolic and mitochondrial systems for NADH- and NADPH-dependent reduction of alpha-lipoic acid. Free Radic Biol Med 22:535-542.
15. Higdon J. 2003. An Evidence-Based Approach to Vitamins and Minerals. New York: Thieme.
16. Humphries KM, Szweda LI. 1998. Selective inactivation of alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase: reaction of lipoic acid with 4-hydroxy-2-nonenal. Biochemistry 37:15835-15841.
17. Kim SY, Kim MY, Mo JS, Park JW, Park HS. 2007. SAG protects human neuroblastoma SH-SY5Y cells against 1-methyl-4-phenylpyridinium ion (MPP+)-induced cytotoxicity via the downregulation of ROS generation and JNK signaling. Neurosci Lett 413:132-136.
18. Kirsch M, De Groot H. 2001. NAD(P)H, a directly operating antioxidant? FASEBJ 15:1569-1574.
19. Kopin IJ. 1987. Toxins and Parkinson's disease: MPTP parkinsonism in humans and animals. Adv Neurol 45:137-144.
20. Kuhn W, Muller T, Winkel R, Danielczik S, Gerstner A, Hacker R, Mattern C, Przuntek H. 1996. Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis. J Neural Transm 103:1187-1193.
21. Liu J. 2008. The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. Neurochem Res 33:194-203.
22. Liu J, Ames BN. 2005. Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease. Nutr Neurosci 8:67-89.
23. Pearl SM, Antion MD, Stanwood GD, Jaumotte JD, Kapatos G, Zigmond MJ. 2000. Effects of NADH on dopamine release in rat striatum. Synapse 36:95-101.
24. Pendleton RG, Parvez F, Sayed M, Hillman R. 2002. Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster. J Pharmacol Exp Ther 300:91-96.
25. Perier C, Tieu K, Guegan C, Caspersen C, Jackson-Lewis V, Carelli V, Martinuzzi A, Hirano M, Przedborski S, Vila M. 2005. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci U S A 102:19126-19131.
26. Schulz JB, Henshaw DR, Matthews RT, Beal MF. 1995. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp Neurol 132:279-283.
27. Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, Cookson MR, Greenamyre JT. 2002. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 22:7006-7015.
28. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M. 2002. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59:1541-1550.
29. Sun L, Luo C, Long J, Wei D, Liu J. 2006. Acrolein is a mitochondrial toxin: Effects on respiratory function and enzyme activities in isolated rat liver mitochondria. Mitochondrion 6:136-142.
30. Vrecko K, Storga D, Birkmayer JG, Moller R, Tafeit E, Horejsi R, Reibnegger G. 1997. NADH stimulates endogenous dopamine biosynthesis by enhancing the recycling of tetrahydrobiopterin in rat phaeochromocytoma cells. Biochim Biophys Acta 1361:59-65.
31. Yazdani U, German DC, Liang CL, Manzino L, Sonsalla PK, Zeevalk GD. 2006. Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+). Exp Neurol 200:172-183.